Sutro Biopharma (STRO)
Develops site-specific and dual-payload antibody-drug conjugates for oncology using cell-free protein synthesis.
$20.47
At close−0.35 (−1.68%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
estimated · in 63 days
EPS estimate
−$1.66
Revenue estimate
$13.6M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.89−$0.91−$0.14−$6.70−$5.29−$2.94−$2.33Pending
Estimate−$0.86−$0.63−$0.39−$4.20−$8.16−$2.32−$2.19−$1.66
Surprise−3.5%−44.4%+64.1%−59.5%+35.2%−26.7%−6.4%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$14.8M$17.4M$63.7M$9.7M$11.7M$14.5M$9.8MPending
Estimate$12.2M$15.0M$8.9M$10.1M$9.3M$8.9M$12.0M$13.6M
Surprise+21.8%+16.0%+616.6%−4.4%+25.8%+63.3%−17.7%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$1.66 | — | — |
| Aug 2026 | −$2.19 | −$2.33 | −6.4% |
| May 2026 | −$2.32 | −$2.94 | −26.7% |
| Mar 2026 | −$8.16 | −$5.29 | +35.2% |
| Nov 2025 | −$4.20 | −$6.70 | −59.5% |
The latest year is open to everyone — the 34 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Apr 2019 | |||
| Nov 2018 | |||
| Sep 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$1.66 | — | — | $13.6M | — | — | — |
| Aug 12, 2026 | −$2.19 | −$2.33 | −6.4% | $12.0M | $9.8M | −17.7% | −14.9% |
| May 14, 2026 | −$2.32 | −$2.94 | −26.7% | $8.9M | $14.5M | +63.3% | +1.4% |
| Mar 23, 2026 | −$8.16 | −$5.29 | +35.2% | $9.3M | $11.7M | +25.8% | +10.5% |
| Nov 6, 2025 | −$4.20 | −$6.70 | −59.5% | $10.1M | $9.7M | −4.4% | −13.4% |
The latest year is open to everyone — the 34 quarters behind it read with an account. Sign in | |||||||
| Aug 7, 2025 | |||||||
| May 8, 2025 | |||||||
| Mar 13, 2025 | |||||||
| Nov 13, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 13, 2024 | |||||||
| Mar 25, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 15, 2023 | |||||||
| Mar 30, 2023 | |||||||
| Nov 8, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 9, 2022 | |||||||
| Feb 28, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 9, 2021 | |||||||
| May 7, 2021 | |||||||
| Mar 18, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 11, 2020 | |||||||
| Mar 16, 2020 | |||||||
| Nov 8, 2019 | |||||||
| Aug 14, 2019 | |||||||
| May 15, 2019 | |||||||
| Apr 1, 2019 | |||||||
| Nov 14, 2018 | |||||||
| Sep 26, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Dec 31, 2017 | |||||||
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||